Capricor Therapeutics, Inc. beat EPS estimates 0% of the time across 3 reported quarters (0 beats, 3 misses), averaging -16.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.58 | $-0.70 | -20.7% | Miss | |
| Q1 FY26 | $-0.55 | $-0.59 | -7.3% | Miss | Q1 FY26 call |
| Q4 FY25 | $-0.51 | $-0.62 | -21.6% | Miss |
Back to CAPR overview · CAPR holders · CAPR KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.